Trial Profile
A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- Acronyms AMYDARA
- 08 Jul 2021 Status changed from active, no longer recruiting to completed.
- 27 Feb 2020 Results published in the Blood
- 02 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.